Generative Artificial Intelligence (AI) In Drug Discovery Outlook 2034: Key Drivers, Trends, and Market Frontiers
Discover trends, market shifts, and competitive outlooks for the generative artificial intelligence (ai) in drug discovery industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Current and Projected Market Size of the Generative Artificial Intelligence (AI) In Drug Discovery Market Through 2034?
The market size for generative artificial intelligence (AI) in drug discovery has seen significant growth in the recent past. The market is estimated to expand from a valuation of $0.19 billion in 2024 to $0.25 billion in 2025, at a compound annual growth rate (CAGR) of 30.9%. Factors contributing to this growth during the historic period include the rising incidence of chronic diseases, advancements in drug discoveries and clinical trials, embrace of AI in healthcare and drug development, the expansion of biotech industries, and growing government support.
The market size of generative artificial intelligence (AI) in the field of drug discovery is predicted to experience substantial growth in the following years. With a compound annual growth rate (CAGR) of 30.6%, it is expected to reach a value of $0.74 billion by 2029. The substantial growth during the forecasted period can be attributed to factors such as the need for cost-effective drug discovery stimulating the adoption of generative AI, an increase in collaborations among market participants, enhanced computational capacity, combination of generative AI with other burgeoning technologies, and accelerated drug development. Key trends projected for the forecast period encompass cutting-edge technologies, the union of generative AI and experimental biology, high-throughput screening for expedited drug discovery pipelines, the creation of AI-based platforms for drug repurposing, and a surge in the adoption of cloud-powered AI solutions for joint drug discovery endeavors.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Generative Artificial Intelligence (AI) In Drug Discovery Market?
The proliferation of clinical trials is projected to drive the expansion of generative AI in the drug discovery industry. Clinical trials, which involve human participants, determine the safety and efficacy of novel medical procedures or treatments with the goal of compiling scientific evidence regarding their appropriateness for human application. The surge in clinical trials is mainly due to strides in medical research, escalating disease prevalence, changes in regulations, the internationalization of clinical research, patient support and awareness, industry rivalry, technological advancements, and funding prospects. The data from clinical trials powers generative AI systems, hastening the drug discovery process by predicting interactions and formulating compounds. This collaboration allows for customized medicine, enhances treatment effectiveness, better patient outcomes, and transforms the pharmaceutical sector. For instance, based on information from ClinicalTrials.gov, a U.S. clinical trial registry, by the end of 2023, a total of 477,234 clinical trials had been registered worldwide, which signifies an uptick from the 437,512 trials that were registered in 2022. Thus, the escalating number of clinical trials is spurring the uptake of generative AI in the drug discovery market.
Which Segments in the Generative Artificial Intelligence (AI) In Drug Discovery Offer the Most Growth?
The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp
Which Areas Are Leading Regions in the Generative Artificial Intelligence (AI) In Drug Discovery Market Expansion Across the Globe?
North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive the Generative Artificial Intelligence (AI) In Drug Discovery Market’s Growth?
Leading firms in the generative AI drug discovery market are engineering advanced tools powered by AI to expedite drug discovery procedures. AI-empowered tools hasten drug development by optimizing drug discovery, design, and clinical trials with the aid of predictive analytics and machine learning. They enhance productivity in areas like target identification, compound screening, including AI-assisted virtual screening, preclinical development, regulatory compliance, and manufacturing processes. For example, Google Cloud, a well-known cloud computing service from Google based in the US, launched two innovative AI-focused solutions in May 2023. These solutions, known as the Target and Lead Identification Suite and the Multiomics Suite, aim to enhance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite guides researchers in comprehending amino acid functions and predicting protein structures. Meanwhile, the Multiomics Suite expedites the analysis and comprehension of genomic data, making it easier to develop personalized treatments.
View the full report here:
What Are the Key Elements That Define the Generative Artificial Intelligence (AI) In Drug Discovery Market?
Generative AI in drug discovery involves using advanced machine learning, especially generative models, to create and identify new pharmaceutical compounds. These AI systems analyze extensive data, including chemical properties, biological activity, and existing drug information to predict and generate novel molecules with potential therapeutic benefits. The primary aim of generative AI in drug discovery is to accelerate the creation and identification of novel pharmaceutical compounds with potential therapeutic effects, optimizing the drug development process by leveraging extensive data to predict and generate new molecules efficiently.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16067
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
